COMPANY PROFILE

公司简介

Ningbo Kunpeng Biotech Co., Ltd. was established in April 2016. The company takes "providing medicines, technologies and services for human disease control" as its mission and is committed to the research, development, production and sales of human drugs. In the field of diabetes treatment drugs, the company has developed a product including recombinant human insulin, insulin glargine, insulin aspart, liraglutide and other pharmaceutical products using the unique "protein fixed-point modification technology" platform and subversive process engineering technology development. chain. At the same time, research on new drugs such as new long-acting insulin and GLP-1 analogs is also actively underway. The company has a complete R&D and pilot test platform, and has formed a team of R&D, production and quality management talents including several domestic and foreign technical experts. In the first phase of industrialization, RMB 200 million Details>>

独有的“蛋白定点修饰技术”

Us r&d base


It has established a joint research and development center in cooperation with Texas A&M and signed an agreement on personnel training and technical exchange

Details

Ningbo r&d base


Ningbo research and development center jointly established with the Yangtze river delta research institute of tsinghua university.

Details

Suzhou r&d base


Kunshan small nucleic acid base has built a biomedical entrepreneurship service platform, including analysis and testing platform, pilot plant platform, CRO professional service platform and medical database.

Details

PRODUCT CENTER

产品中心

NEWS CENTER

新闻中心